Last reviewed · How we verify
NCT04458571
Effect of CRRT Duration on Solute Removal
trial in AKI in 112 participants. Completed in 21 December 2022.
21 December 2022
Quick facts
| Lead sponsor | University of Colorado, Denver |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 112 |
| Start date | 1 October 2020 |
| Primary completion | 21 December 2022 |
| Estimated completion | 21 December 2022 |
| Sites | 1 location across United States |
Conditions studied
Sponsor
University of Colorado, Denver
Who can join
18 and older, any sex, with AKI or Sepsis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The only FDA approved treatment for acute kidney injury(AKI) for patients is Dialysis-also known as renal replacement therapy(RRT). Continuous RRT(CRRT) is the preferred method in the ICU. Patients receiving CRRT with AKI will be recruited to the study where blood and effluent will be collect prior to CRRT initiation and Day 1,2,and 3 following. Metabolites will be assessed to determine solute removal, and also to identify the time at which solute removal has reached steady state. This will help determine the best duration of CRRT.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Procalcitonin levels in septic and nonseptic subjects with AKI and ESKD prior to and during continuous kidney replacement therapy (CKRT).
Foulon N, Haeger SM, Okamura K, He Z, et al · · 2025 · cited 2× · PMID 40307866 · DOI 10.1186/s13054-025-05414-7
Verify or expand the search:
- PubMed search for NCT04458571
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for AKI
Currently open trials in the same condition.
- NCT07262320 — Epidemiology and Processes of Care for Renal Replacement Therapy in Acute Kidney Injury in Latin America · recruiting
- NCT06596811 — Research on the Risk Warning Model and Prevention Strategies for Acute Kidney Injury Associated With Cyclosporine Based · active not recruiting
- NCT06596798 — Deep Learning Model and Risk Factors for Tacrolimus-related Acute Kidney Injury · active not recruiting
- NCT04216927 — NO During CPB in Neonates to Reduce Risk of AKI · Phase 3 · recruiting
- NCT04114747 — Renal Physiology During Continuous Renal Replacement Therapy · NA · recruiting
Other University of Colorado, Denver trials
Trials by the same sponsor.
- NCT07292285 — The Surveillance Nonoperative Watch & Wait (SNOWW) Rectal Cancer Trial. · not yet recruiting
- NCT07021937 — Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity · Phase 3 · not yet recruiting
- NCT07453732 — Banana Leaves as a Wound Dressing for Partial Thickness Second Degree Burns in Adult Patients. · NA · not yet recruiting
- NCT07038278 — 5-AminoLevulinic Acid Aided Resection Margins in Sarcoma · EARLY_PHASE1 · not yet recruiting
- NCT07279558 — Cannabidiol and Alcohol Use Disorder Phenotypes · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04458571 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Colorado, Denver
- Last refreshed: 14 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04458571.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing